Envestnet Asset Management
CRNX icon

Envestnet Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Envestnet Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.47M Sell
146,216
-4,443
-3% -$165K ﹤0.01% 2401
2026
Q1 		$5.47M Buy
150,659
+20,296
+16% +$907K ﹤0.01% 2259
2025
Q4 		$6.07M Buy
130,363
+77,698
+148% +$3.46M ﹤0.01% 2044
2025
Q3 		$2.19M Sell
52,665
-1,593
-3% -$50.9K ﹤0.01% 2819
2025
Q2 		$1.56M Sell
54,258
-2,433
-4% -$75.1K ﹤0.01% 2995
2025
Q1 		$1.9M Sell
56,691
-6,386
-10% -$238K ﹤0.01% 2770
2024
Q4 		$3.23M Buy
63,077
+8,751
+16% +$490K ﹤0.01% 2383
2024
Q3 		$2.78M Buy
54,326
+2,535
+5% +$131K ﹤0.01% 2461
2024
Q2 		$2.32M Buy
51,791
+9,859
+24% +$455K ﹤0.01% 2503
2024
Q1 		$1.96M Buy
+41,932
New +$1.64M ﹤0.01% 2580

Other funds holding CRNX

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
BSA
Braun Stacey Associates New York $3.53B AUM 63.32% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Envestnet Asset Management's CRNX Position: Q2 2026 in Review

Envestnet Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 2.9% in Q2 2026, selling an estimated $165K and leaving 146,216 shares worth $5.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Envestnet Asset Management first reported a position in CRNX in Q1 2024 and has held it in 10 quarters since. The position peaked at $6.07M in Q4 2025. 73 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Envestnet Asset Management held 146,216 shares of Crinetics Pharmaceuticals worth $5.47M as of Q2 2026.
  • Envestnet Asset Management sold 4,443 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $165K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #2401 holding.
  • Envestnet Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Envestnet Asset Management's Crinetics Pharmaceuticals position peaked at $6.07M in Q4 2025.
  • 73 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.